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Mutations in the DBP-Deficiency Protein HSD17B4
Cause Ovarian Dysgenesis, Hearing Loss,
and Ataxia of Perrault Syndrome
Sarah B. Pierce,1,7 Tom Walsh,1,7 Karen M. Chisholm,1,8 Ming K. Lee,1 Anne M. Thornton,1
Agata Fiumara,2 John M. Opitz,3 Ephrat Levy-Lahad,4,5 Rachel E. Klevit,6 and Mary-Claire King1,*
Perrault syndrome is a recessive disorder characterized by ovarian dysgenesis in females, sensorineural deafness in both males and
females, and in some patients, neurological manifestations. No genes for Perrault syndrome have heretofore been identified. A small
family of mixed European ancestry includes two sisters with well-characterized Perrault syndrome. Whole-exome sequencing of
genomic DNA from one of these sisters revealed exactly one gene with two rare functional variants: HSD17B4, which encodes
17b-hydroxysteroid dehydrogenase type 4 (HSD17B4), also known as D-bifunctional protein (DBP). HSD17B4/DBP is a multifunctional
peroxisomal enzyme involved in fatty acid b-oxidation and steroid metabolism. Both sisters are compound heterozygotes for HSD17B4
c.650A>G (p.Y217C) (maternal allele) andHSB17B4 c.1704T>A (p.Y568X) (paternal allele). Themissensemutation is predicted by struc-
tural analysis to destabilize the HSD17B4 dehydrogenase domain. The nonsensemutation leads to very low levels ofHSD17B4 transcript.
Expression of mutant HSD17B4 protein in a compound heterozygote was severely reduced. Mutations in HSD17B4 are known to cause
DBP deficiency, an autosomal-recessive disorder of peroxisomal fatty acid b-oxidation that is generally fatal within the first two years of
life. No females with DBP deficiency surviving past puberty have been reported, and ovarian dysgenesis has not previously been
associated with this illness. Six other families with Perrault syndrome have wild-type sequences of HSD17B4. These results indicate
that Perrault syndrome and DBP deficiency overlap clinically; that Perrault syndrome is genetically heterogeneous; that DBP deficiency
may be underdiagnosed; and that whole-exome sequencing can reveal critical genes in small, nonconsanguineous families.Perrault syndrome (PS [MIM 233400]) is a sex-influenced
disorder characterized by sensorineural deafness in both
males and females and ovarian dysgenesis in females.1
Some patients also have neurological manifestations,
including mild mental retardation and cerebellar and
peripheral nervous system involvement.2,3 Clinical hetero-
geneity of the illness has prompted a possible classification
of Perrault syndrome to type I, static and without neuro-
logical disease, and type II, with progressive neurological
disease.
We evaluated an American family of mixed European
ancestry with two daughters whose clinical manifestations
have been thoroughly described.4,5 In the evaluation by
Fiumara et al.,5 these patients are MK and LK. In addition
to sensorineural deafness and ovarian dysgenesis, both
sisters exhibited short stature, mild mental retardation,
and progressive sensory and motor peripheral neuropathy.
The older sister also had prominent cerebellar involve-
ment, with dysarthria, intention tremor, and ataxia and
MRI studies revealing ‘‘moderately severe’’ atrophy of the
cerebellar hemispheres and vermis.
Because the family is small and not consanguineous,
neither linkage analysis nor homozygositymapping would
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the gene responsible for Perrault syndrome in this family.
A paired-end library was prepared from genomic DNA of
individual 4-01 (Figure 1A) and hybridized to biotinylated
cRNA oligonucleotide baits from the SureSelect Human
All Exon Kit (Agilent Technologies).6 The exome-enriched
library was sequenced with paired-end 76 bp reads on two
lanes of an Illumina Genome Analyzer IIx with the use
of Illumina pipeline v1.6. We used MAQ v0.7.17 to align
the sequence reads to the February 2009 human reference
sequence of the UCSC Genome Browser (GRCh37/hg19).
A total of 5.73 Gb of sequence (376,973,000 pairs of reads)
aligned to the exome target. The proportion of the entire
targeted exome covered by > 10 reads of Q30 or greater
quality was 93.1%. DNA variants were filtered against
dbSNP131 and Phase 3 of the 1000 Genomes project
(March 2010 data release), then classified by predicted
function to include all missense, nonsense, frameshift, or
splice-site alleles. Given that dbSNP includes both disease-
associated and benign alleles, we included in the analysis
known SNPs identified by dbSNP as clinically associated.
Because the pedigree structure of Perrault syndrome in
the family is consistent with autosomal or X-linked reces-
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H.sapiens         PEDLVEALKPEYVAPLVLWLCHESCEENGGLFEVGAGWIGKLRWERT
M.musculus        PEDLVEALKPEYVAPLVLWLCHESCEENGGLFEVGAGWIGKLRWERT
B.taurus          PEDLVEALKPDYVAPLVLWLCHESCEENGGLFEVGAGWIGKLRWERS
M.domesticus      PQDLVDALKPDYVAPLVLWLCHESCEENGGLFEVGAGWIGKLRWERT
G.gallus          PQDLIDAFKPEYVAPLVLWLCHETCMENGSLFEVGAGWIGKLRWERS
X.laevis          PQDLLDALKPEYVTPLVLWLCHERCQETGSLFEVGAGWVGKLRWERS
S.purpuratus      PPDIFEKLKPDYVAPMVAYLSHEECQSTGGIYECGAGWAAKLRWQRT
C.elegans         PQNLVDALKPDYVTPLVTYMVHDSFEESGKVFEAGAGWYGTIQYYKS
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Figure 1. Coumpound Heterozygosity for HSD17B4 Mutations in Family 4
(A) Pedigree of Perrault syndrome family 4.
(B) Validation by Sanger sequencing of HSD17B4 mutations identified in individual 4-01 by whole-exome sequencing. Genomic DNA
was sequenced after amplification with primers flanking exon 9 (50- TGGAAAGGTGTGTCTGATAC-30, 50- CAAATGTAGAACTAAG
TAAAAAC-30) and exon 20 (50- TTGAAAGACAAAGAATTGGC-30, 50-TGAAAACACCAGACAAGCTG-30). Arrows indicate heterozygosity
for chr5:118,824,914A>G, HSD17B4 c.650A>G (p.Y217C), in the upper panel, and for chr5:118,862,851T>A, HSB17B4 c.1704T>A
(p.Y568X), in the lower panel.
(C) Schematic of the HSD17B4 protein.
(D) Diagram of the four steps of peroxisomal b-oxidation (left) and the enzymes by which they are catalyzed (right), using oxidation of
very long chain fatty acids (VLCFA) as an example.
(E) Protein sequence alignment of HSD17B4 orthologs, showing the region surrounding themutated Y217 (indicated in red). The project
was approved by the Human Subjects Division of the University of Washington, and informed consent was obtained from all of the
subjects.analyses. The number of rare variants of each class identi-
fied in the proband is indicated in Table 1. We surveyed all
genes harboring the 207 rare nonsense, missense, frame-
shift, or splice variants for any genes with two such alleles
in this patient.
Only one gene, HSD17B4 (MIM 601860) on chromo-
some 5q23.1, fulfilled this criterion (Table 2). The patient’s
DNA included mutations at chr5:118,824,914A>G, corre-The Americsponding to HSD17B4 c.650A>G (p.Y217C) in exon 9,
and at chr5:118,862,851T>A, corresponding to HSB17B4
c.1704T>A (p.Y568X) in exon 20 (accession no. NM_
000414). An intronless partial pseudogene of HSD17B4 is
located on chr8q24.13. Because the pseudogene duplicates
HSD17B4 exon 20, only 19% of total reads aligned to
chr5:118,862,851 harbor the nonsense mutation. We
encountered similar asymmetry in read number as thean Journal of Human Genetics 87, 282–288, August 13, 2010 283
Table 1. Variants Revealed by Whole-Exome Sequencing in
a Proband with Perrault Syndrome
SBP Indel Total
Number of variants withR 15% of total reads 790 356 1146
Number of nonsense, missense, frameshift,
or splice variants
191 16 207
Number of genes with R 2 nonsense,
missense, frameshift, or splice variants
1
SBP indicates single base pair substitutions; Indel indicates small insertions or
deletions.
Table 2. Number of Wild-Type and Variant Reads at HSD17B4
Chr. Coordinate Variant
Wild-Type
Reads
Variant
Reads Effect
5 118,824,914 A>G 159 129 Y217C
5 118,862,851 T>A 198 47 Y568stopresult of pseudogenization of CHEK28. In contrast, the
pseudogene does not include HSD17B4 exon 9, and 45%
of total reads aligned to chr5:118,824,914 harbor the mis-
sense mutation. PCR amplification and Sanger sequencing
demonstrated that both the proband (4-01) and her sister
(4-02) were compound heterozygotes for both mutations,
with the nonsense allele inherited from their mother
(4-03) and the father an obligate carrier of the missense
mutation (Figures 1A and 1B). The PCR primers used for
mutation validation were unique to the functional copy
on chromosome 5 and did not detect the pseudogene.
Primers for sequencing HSD17B4 are listed in Table S1,
available online.
In order to determine whether both mutant transcripts
were expressed, we sequenced lymphoblast cDNA from
patient 4-02 and from a control individual with wild-type
HSD17B4 sequence. The HSB17B4 c.1704T>A (p.Y568X)
transcript is expressed at very low levels relative to the
HSD17B4 c.650A>G (p.Y217C) transcript (Figure 2A).
This observation suggests that the HSB17B4 c.1704T>A
(p.Y568X) transcript is subjected to nonsense-mediated
decay whereas the HSD17B4 c.650A>G (p.Y217C) is
more stably expressed.
The protein encoded by HSD17B4, 17b-hydroxysteroid
dehydrogenase type 4 (HSD17B4), also known as D-bifunc-
tionalprotein (DBP) andmultifunctionalprotein2 (MFP-2),
is a multifunctional peroxisomal enzyme involved in fatty
acid b-oxidation and steroidmetabolism.9,10HSD17B4 con-
tains three functional domains: an N-terminal 3-hydrox-
yacyl-CoA dehydrogenase domain, a central 2-enoyl-CoA
hydratase domain, and a C-terminal sterol carrier protein
2-like domain (SCP-2L), the final three amino acids of
which form the peroxisomal targeting signal11 (Figure 1C).
The 79 kD full-length HSD17B4 protein is proteolytically
cleaved after peroxisomal import to yield a 35 kD dehydro-
genase unit and a 45 kD hydratase/SCP-2L unit, both of
which are homodimeric.12,13,14,15 The hydratase and dehy-
drogenase domains catalyze sequential steps in fatty acid
b-oxidation (Figure 1D). In addition, the dehydrogenase
domain functions in steroid metabolism to convert the
more active 17b-estradiol to the less active estrone.8 The
sequence and multifunctional nature of HSD17B4 are
highly conserved.8,16 In particular, the Y217 residue that
is mutant in these patients is identical from humans to C.
elegans and is located in a very highly conserved region of284 The American Journal of Human Genetics 87, 282–288, August 1the protein (Figure 1E). HSD17B4 p.Y217C is predicted by
the PolyPhen-2 algorithm to be ‘‘probably damaging’’
with a score of 0.991 and by the Xvar algorithm to have
‘‘medium functional impact’’ with a score of 1.615. Neither
HSD17B4 c.650A>G (p.Y217C) nor HSB17B4 c.1704T>A
(p.Y568X) was present in 1092 control individuals (2184
control chromosomes).
Mutations in HSD17B4 cause DBP deficiency (MIM
261515), an autosomal-recessive disorder of peroxisomal
fatty acid b-oxidation that is generally fatal within the first
two years of life. Patients with classical DBP deficiency
present with hypotonia and seizures by one month of age.
They have dysmorphic features and hearing and vision
impairments, and they generally make no developmental
progress.9 DBP deficiency results in the accumulation of
b-oxidation substrates, includingvery longchain fatty acids
(VLCFA), branched chain fatty acids, and bile acid interme-
diates that are all detectable in serum or cultured patient
fibroblasts. In addition, the presence of DBP can be directly
examined by immunoblotting, and DBP enzyme activity
can be measured in fibroblast samples.9 DBP deficiency
can be classified into three types, each based on which of
the two DBP enzymatic activities are diminished. In type
I, bothhydratase anddehydrogenase activities aredeficient,
type II is a specific hydratase deficiency, and type III is
a specific dehydrogenase deficiency.9 Different classes of
HSD17B4 mutations are associated with each type of DBP
deficiency. All DBP deficiency patients described to date
are homozygous or compound heterozygous for mutations
in HSD17B4. Type I deficiency is generally associated with
nonsense mutations, frameshift mutations, or in-frame
deletions of 20 or more residues in the dehydrogenase
domain. In patients with type I deficiency, HSD17B4
protein is almost always undetectable in fibroblasts. Type
II deficiency is associated with missense mutations or
in-frame deletions in the hydratase domain, and type III
deficiency is associated with missense mutations or single
amino acid deletions in the dehydrogenase domain.17
The genotype of the affected sisters in family 4 does not
correspond exactly to any of these types. HSD17B4
p.Y568X is a mutation of the sort associated with type I
deficiency. HSD17B4 p.Y217C is a missense mutation in
the dehydrogenase domain, so generally associated with
type III deficiency. Interestingly, one of the more mildly
affected cases in the literature, who was alive at 7.5 years,
is a compound heterozygote for type I and type II alleles.16
Differences in transcript expression of the two HSD17B4
mutant alleles in the patients in family 4 (Figure 2A) moti-
vated us to examine expression of HSD17B4 protein in3, 2010
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Figure 2. Expression of HSD17B4
Mutant Transcripts and Protein
(A) Expression of the two mutant tran-
scripts of HSD17B4. Gene-specific cDNA
for HSD17B4 was prepared from lympho-
blast RNA of patient 4-02 and an unrelated
control. cDNA was generated from total
RNA with a primer located in exon 23
(50- CCAGAACCACTTTTCAGGTCAATAG
TCCAC-30), amplified with primer pairs
spanning exons 7–12 (50-GGGTTCATTCC
AAGTGACAC-30, 50-TCCTGATGTTGCTG
TAGACG-30) and exons 17–22, (50- GCCA
TACCTAATAGACCTCC-30, 50- CAGCATT
TACTTTCTTCACC-30), and Sanger se-
quenced. The upper panels indicate
sequence from patient 4-02, whose
genomic DNA is heterozygous at nucleo-
tide positions c.650, c.1687 (rs11205),
and c.1704. The cDNA sequence harboring
the GGT haplotype, which carries the
missense allele G at c.650, the G allele at
c.1687, and the wild-type allele T at
c.1704 is more highly expressed than the
sequence harboring the AAA haplotype,
which carries the wild-type allele A at
c.650, the A allele at c.1687, and the
nonsense allele A at c.1704. The lower
panels indicate sequence from an unre-
lated control, who is heterozygous at
c.1687 and wild-type at c.650 and c.1704.
The two alleles of the SNP at c.1687 appear
equally expressed in the lymphoblast
cDNA of the control.
(B) Lymphoblast cell lysates (50 mg) of
patients (4-02 and 4-03) and controls
(C1–C4) and Huh7 lysates (10 mg) were
analyzed by immunoblotting using
primary antibodies rabbit anti-HSD17B4
(Sigma) and mouse anti-b-actin (Sigma)
and IRDye-conjugated secondary anti-
bodies (LI-COR Biosciences). Full-length
HSD17B4 (79 kD) and the processed dehy-
drogenase domain (35 kD) are indicated.these patients by immunoblotting. Using an antibody
directed against the dehydrogenase domain of HSD17B4,
we compared the expression of HSD17B4 in lymphoblast
lysate from affected individual 4-02 and her mother,
4-03, versus HSD17B4 expression in lymphoblast lysate
from four unrelated, healthy individuals with wild-type
HSD17B4 sequences and in the human liver cell line
Huh7. In all control samples and in Huh7, full-length
HSD17B4 protein and the 35 kD dehydrogenase domain
are detected (Figure 2B). In the sample from the unaffected
mother, 4-03, who is heterozygous for HSD17B4 p.Y568X,
there is a noticeable reduction in the amounts of full-
length 79 kD protein and processed 35 kD dehydrogenase
domain, and there is no evidence of a truncated protein.
The reduced level of the transcript encoding HSD17B4
p.Y568X (Figure 2A) suggests that nonsense-mediated
decay of the mutant RNA is the primary explanation for
the reduced protein level, but the stability of the truncatedThe Americprotein may also be reduced. In the sample from affected
sister 4-02, who is compound heterozygous for HSD17B4
p.Y568X and HSD17B4 p.Y217C, the amounts of both
full-length protein and the dehydrogenase domain are
further reduced. These results are consistent with previous
observations that nonsense and other truncatingHSD17B4
mutations generally lead to a complete loss of pro-
tein,14,16,18 which would explain the dramatic decrease
in the full-length and 35 kD proteins in individual 4-03.
Some missense mutations also appear to lead to a decrease
in the amount of protein detected,16,17 consistent with the
further reduction in the amount of HSD17B4 in individual
4-02.
Because the affected sisters likely express only protein
with the HSD17B4 p.Y217C mutation, we predict that
they have type III DBP deficiency, with a defect in dehydro-
genase activity. A crystal structure of the human dehydro-
genase domain in complex with nicotinamide adeninean Journal of Human Genetics 87, 282–288, August 13, 2010 285
Figure 3. Structure of the HSD17B4
Dehydrogenase Domain
A ribbon representation of the HSD17B4
dehydrogenase domain in complex with
NAD (PDB 1GZ6), showing the region
surrounding the mutated residue Y217.
The A and B chains of the homodimer
are colored green and blue, respectively.
NAD is represented as sticks within the
binding site. As explained in the text,
substitution of cysteine for tyrosine at
position 217 is predicted to abrogate the
cation-p orbital interaction of Y217 and
R258 and thus the critical charged interac-
tion of R258with D303, leading to destabi-
lization of the dehydrogenase domain and
loss of specific activity of the enzyme.dinucleotide (NAD [PDB 1GZ6]) allows us to examine the
structural role of Y217 and to predict the effect of the
HSD17B4 p.Y217C substitution on dehydrogenase func-
tion. The HSD17B4 dehydrogenase domain exists as a
‘‘domain-swapped’’ dimer, in which the C-terminal region
of one polypeptide chain crosses over to complete the
functional structure of the other polypeptide chain and
vice versa (Figure 3). In particular, the C-terminal helix
aH of chain B (dark blue) forms a lid over the NAD-binding
site and interacts with two short helices in chain A (dark
green) that surround the NAD-binding site and contribute
catalytic residues. The aromatic side chain of Y217 points
away from the NAD-binding site and is involved in
a network of interactions predicted to stabilize the func-
tional dimeric structure. Specifically, Y217 from chain A
(yellow and red spheres) is in close contact to the side
chain of R258 from chain B (gray and blue spheres) in
a cation-p orbital interaction.19 R258 is also in a position
to make a favorable charged interaction with the nega-
tively charged side chain of D303 on chain B (gray and
red spheres). D303 is at the extreme C-terminal end of
helix aH, so the interaction network is likely responsible
for holding this helix in place, thereby completing the
NAD-binding site. R258 is part of the interaction surface
for the coenzyme-A moiety of the substrate,20 so its proper
placement in the structure may affect substrate binding as
well. Substitution of the aromatic side chain of Y217 with
a small, hydrophilic cysteine residue is predicted to desta-
bilize the conformation of the dehydrogenase domain
and thereby decrease specific activity of the enzyme.
A known DBP type III deficiency mutation at the adjacent
position V218,16,21 whose side chain points directly into
the NAD-binding site, is predicted to disrupt NAD bind-
ing16 and is likely to be more severe than Y217C.
Although DBP deficiency is commonly fatal in early
childhood, a small number of type II and type III patients
have been documented as surviving beyond 8 yrs of
age.16,20,22,23 All of these cases were associated with
missense mutations in the hydratase or dehydrogenase286 The American Journal of Human Genetics 87, 282–288, August 1domain that, in most cases, were predicted to result in
only minor structural effects and probable retention of
residual enzyme activity. In many of these cases, there
was little or no accumulation of b-oxidation substrates in
serum, and DBP deficiency was detectable only by analysis
of cultured fibroblasts.
It is likely that the sisters in our study are even more
mildly affected than these previously documented cases.
They were last examined at the ages of 27 and 16 and are
therefore older than almost all documented cases, but
notably, they share the critical features of older DBP-defi-
ciency cases. An 8-yr-old DBP-deficient girl described by
Soorani-Lunsing et al.21 had hearing loss and ataxia,
peripheral polyneuropathy, and cerebellar atrophy. Her
clinical course was characterized by a period of delayed
development followed by progressive neurological deterio-
ration, all similar to that of the older sister we studied.
Serum VLCFA levels were normal in this girl,21 as in the
older sister we report, who at age 23 had normal serum
levels of VLCFA and phytanic acid.5 Hearing loss, poly-
neuropathy, cerebellar atrophy, and progressive loss of
motor skills have also been observed in other long-term
DBP-deficiency survivors, again with little or no abnormal-
ities in VLCFA and other b-oxidation substrates.16,24 An
important conclusion to gather from these observations
is that mild DBP deficiency may be underdiagnosed if cases
with normal VLCFA or phytanic acid levels are not tested
for enzymatic HSD17B4/DBP activity.
Except for the milder course of their disease, the young
women we report have ovarian dysgenesis as the major
clinical feature distinguishing them from other DBP-defi-
ciency cases, and the combination of deafness and ovarian
dysgenesis led to the diagnosis of Perrault syndrome.
Although progressive neurological symptoms have been
described in Perrault syndrome, ovarian dysgenesis has
not previously been associated with DBP deficiency. How-
ever, very few patients have survived to the age of puberty,
and none of those documented patients have been female.
Our results suggest that mutations in HSD17B4 leading to3, 2010
DBP deficiency that is mild enough to allow survival to the
age of puberty are likely to cause ovarian dysgenesis in
females in addition to the known neurological defects.
HSD17B4 mutations are the first identified cause of
Perrault syndrome. Although HSD17B4 should be exam-
ined in other Perrault cases, especially those with neuro-
logical features, it is clear that Perrault syndrome is genet-
ically heterogeneous. We have ruled out mutations in
HSD17B4 as the cause of Perrault syndrome in six other
families with hearing loss and ovarian dysgenesis, both
with and without neurological symptoms.Supplemental Data
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